TrialJournal for immunotherapy of cancer2021

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.

Andrea Ardizzoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.